Keith C. Bible, MD, PhD, medical oncologist, Mayo Clinic, discusses the impact that lenvatinib (Lenvima) has had on the treatment landscape of differentiated thyroid cancer (DTC).

It is a plus to have another agent, such as lenvatinib, in this space as sorafenib demonstrates more modest activity in patients. Lenvatinib also elicits higher response rates in patients versus sorafenib, Bible explains. In patients with aggressive symptomatic disease, lenvatinib is a more cytoreductive approach that can help improve symptoms.

The approval of lenvatinib gives clinicians the opportunity to provide another therapy option to patients with DTC, Bible says.

View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Multidisciplinary Head and Neck Cancer Symposium

Keith C. Bible, MD, PhD, medical oncologist, Mayo Clinic, discusses the impact that lenvatinib (Lenvima) has had on the treatment landscape of differentiated thyroid cancer. 

Dr. Bible on Impact of Lenvatinib on Treatment Landscape of DTC